|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Nurix Therapeutics, Inc. (NRIX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,040,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,577 |
30,969 |
38,399 |
50,751 |
| Total Sell Value |
$114,287 |
$279,304 |
$351,677 |
$512,044 |
| Total People Sold |
3 |
3 |
4 |
4 |
| Total Sell Transactions |
4 |
9 |
16 |
32 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Van Houte Hans |
Chief Financial Officer |
• – – |
2024-02-16 |
4 |
AS |
$10.02 |
$68,223 |
D/D |
(6,812) |
68,333 |
|
- |
|
| Ring Christine |
Chief Legal Officer |
• – – |
2024-01-30 |
4 |
S |
$7.99 |
$14,063 |
D/D |
(1,760) |
17,427 |
|
- |
|
| Ring Christine |
Chief Legal Officer |
• – – |
2024-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,924 |
19,187 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2024-01-30 |
4 |
S |
$7.99 |
$18,649 |
D/D |
(2,334) |
36,402 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2024-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,207 |
38,736 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2024-01-30 |
4 |
S |
$7.99 |
$13,352 |
D/D |
(1,671) |
75,145 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2024-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,886 |
76,816 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2023-12-20 |
4 |
AS |
$10.00 |
$35,421 |
D/D |
(3,541) |
71,930 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2023-12-19 |
4 |
AS |
$10.00 |
$109,093 |
D/D |
(10,906) |
75,471 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2023-10-31 |
4 |
S |
$5.20 |
$8,487 |
D/D |
(1,633) |
33,529 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2023-10-31 |
4 |
S |
$5.20 |
$5,613 |
D/D |
(1,080) |
86,377 |
|
- |
|
| Ring Christine |
Chief Legal Officer |
• – – |
2023-10-31 |
4 |
S |
$5.20 |
$6,403 |
D/D |
(1,232) |
15,263 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2023-10-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,207 |
35,162 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2023-10-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,886 |
87,457 |
|
- |
|
| Ring Christine |
Chief Legal Officer |
• – – |
2023-10-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,924 |
16,495 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2023-07-31 |
4 |
S |
$9.65 |
$12,020 |
D/D |
(1,245) |
82,571 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2023-07-31 |
4 |
S |
$9.65 |
$13,710 |
D/D |
(1,420) |
12,544 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2023-07-31 |
4 |
S |
$9.65 |
$18,189 |
D/D |
(1,884) |
29,955 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2023-07-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,886 |
83,816 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2023-07-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,924 |
13,964 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2023-07-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,207 |
31,839 |
|
- |
|
| Wolff Stefani |
EVP and COO |
• – – |
2023-05-01 |
4 |
S |
$9.88 |
$3,378 |
D/D |
(342) |
6,113 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2023-05-01 |
4 |
S |
$9.88 |
$6,736 |
D/D |
(682) |
10,040 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2023-05-01 |
4 |
S |
$9.88 |
$7,121 |
D/D |
(721) |
78,930 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2023-05-01 |
4 |
S |
$9.88 |
$11,219 |
D/D |
(1,136) |
26,632 |
|
- |
|
166 Records found
|
|
Page 1 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
